Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CLDX – Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.
CLDX
$21.35
Name : Celldex Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,417,516,160.00
EPSttm : -2.7
finviz dynamic chart for CLDX
Celldex Therapeutics, Inc.
$21.35
9.32%
$1.82

Float Short %

14.15

Margin Of Safety %

Put/Call OI Ratio

0.42

EPS Next Q Diff

-0.07

EPS Last/This Y

-0.98

EPS This/Next Y

-0.68

Price

21.33

Target Price

57.25

Analyst Recom

1.29

Performance Q

3.29

Relative Volume

0.98

Beta

1.14

Ticker: CLDX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08CLDX19.520.680.678172
2025-05-09CLDX18.340.670.318231
2025-05-12CLDX20.180.650.288512
2025-05-13CLDX19.610.64999.998601
2025-05-14CLDX18.950.640.008606
2025-05-15CLDX20.080.640.008567
2025-05-16CLDX20.450.570.009138
2025-05-19CLDX20.910.530.005970
2025-05-20CLDX20.490.430.046949
2025-05-21CLDX19.930.420.007002
2025-05-22CLDX20.390.40999.997301
2025-05-23CLDX20.380.450.007580
2025-05-27CLDX19.80.450.207581
2025-05-28CLDX18.540.452.007591
2025-05-29CLDX19.820.450.747596
2025-05-30CLDX19.770.450.067629
2025-06-02CLDX19.970.420.758080
2025-06-03CLDX19.850.430.008125
2025-06-04CLDX19.670.420.008147
2025-06-05CLDX19.510.420.178156
2025-06-06CLDX21.360.420.118176
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08CLDX19.51-32.6-72.6-3.26
2025-05-09CLDX18.32-32.6-19.3-3.26
2025-05-12CLDX20.18-32.6-110.4-3.26
2025-05-13CLDX19.62-53.0-18.0-3.43
2025-05-14CLDX18.92-55.8-13.6-3.43
2025-05-15CLDX20.12-55.8-65.1-3.43
2025-05-16CLDX20.45-55.8-40.7-3.43
2025-05-19CLDX20.91-55.8-42.9-3.43
2025-05-20CLDX20.50-55.8-22.5-3.43
2025-05-21CLDX19.96-55.8-19.2-3.43
2025-05-22CLDX20.37-55.8-42.5-3.43
2025-05-23CLDX20.34-55.8-31.3-3.43
2025-05-27CLDX19.78-55.8-18.2-3.43
2025-05-28CLDX18.84-55.8-8.0-3.43
2025-05-29CLDX19.83-55.8-65.7-3.43
2025-05-30CLDX19.78-55.8-30.5-3.43
2025-06-02CLDX19.97-55.8-37.7-3.43
2025-06-03CLDX19.87-55.8-29.2-3.43
2025-06-04CLDX19.67-55.8-27.0-3.43
2025-06-05CLDX19.53-55.8-28.1-3.43
2025-06-06CLDX21.33-55.8-79.9-3.43
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08CLDX0.6910.0513.57
2025-05-09CLDX0.6910.0513.57
2025-05-12CLDX0.6911.0413.92
2025-05-13CLDX0.0011.0413.92
2025-05-14CLDX0.0011.0413.92
2025-05-15CLDX0.0011.0413.92
2025-05-16CLDX0.0011.0413.92
2025-05-19CLDX0.005.4313.97
2025-05-20CLDX0.005.4313.97
2025-05-21CLDX0.005.4313.97
2025-05-22CLDX0.005.4313.97
2025-05-23CLDX0.005.4313.97
2025-05-27CLDX0.00-5.7513.97
2025-05-28CLDX0.00-5.7514.15
2025-05-29CLDX0.00-5.7514.15
2025-05-30CLDX0.00-5.7514.15
2025-06-02CLDX0.00-5.0714.15
2025-06-03CLDX0.00-5.0714.15
2025-06-04CLDX0.00-5.0714.15
2025-06-05CLDX0.00-5.0714.15
2025-06-06CLDX0.00-5.0714.15
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.81

Avg. EPS Est. Current Quarter

-0.84

Avg. EPS Est. Next Quarter

-0.88

Insider Transactions

Institutional Transactions

-5.07

Beta

1.14

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

24

Growth Score

37

Sentiment Score

19

Actual DrawDown %

62.7

Max Drawdown 5-Year %

-73.1

Target Price

57.25

P/E

Forward P/E

PEG

P/S

187.5

P/B

2.02

P/Free Cash Flow

EPS

-2.7

Average EPS Est. Cur. Y​

-3.43

EPS Next Y. (Est.)

-4.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2366.07

Relative Volume

0.98

Return on Equity vs Sector %

-49.5

Return on Equity vs Industry %

-31.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.16

EBIT Estimation

-79.9
Celldex Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 186
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
stock quote shares CLDX – Celldex Therapeutics, Inc. Stock Price stock today
news today CLDX – Celldex Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CLDX – Celldex Therapeutics, Inc. yahoo finance google finance
stock history CLDX – Celldex Therapeutics, Inc. invest stock market
stock prices CLDX premarket after hours
ticker CLDX fair value insiders trading